Ad5/RGD-Luciferase Chimeric Adenovirus

Ad5/RGD-luciferase chimeric adenovirus is a genetically engineered viral vector that utilizes an alternative cell entry pathway to enhance gene delivery. This vector possesses a modified fibrin sphere in which an arginine-glycine-aspartic acid (RGD) peptide motif is inserted into the HI loop of the Ad5 fibrin. This modification allows the adenovirus to bypass the need for Coxsackievirus and adenovirus receptor (CAR) and instead bind directly to αvβ3 and αvβ5 integrins on the surface of target cells. These integrins are widely expressed in various cell types, including vascular endothelial cells, certain tumor cells, and immune cells such as dendritic cells, which typically exhibit low CAR expression levels. The vector is non-replicating and carries a firefly luciferase reporter gene, enabling highly sensitive and quantitative detection of gene expression via bioluminescence assays.

The application of Ad5/RGD-luciferase chimeric adenovirus is significant in immunological and vascular biology research. It is commonly used to transduce dendritic cells for cancer immunotherapy research. Compared to standard Ad5 vectors, RGD-integrin interactions enhance gene transfer efficiency, leading to better expression of immunomodulatory factors. In the laboratory, luciferase reporter genes can sensitively detect the distribution and persistence of gene expression in in vitro cell cultures and in vivo animal models. Researchers have used this system to track viral tropism in different tissues and evaluate the effectiveness of integrin-targeted therapies in tumor growth and angiogenesis. Furthermore, the Ad5/RGD platform is a valuable tool for optimizing viral delivery protocols and conducting high-throughput drug screening to modulate transduction efficiency or cellular responses to viral infection.